Substituted pyrimidines as cannabinoid CB1 receptor ligands

Area of Science:

• Medicinal Chemistry
• Neuropharmacology
• Drug Discovery

Background:

• Cannabinoid CB1 receptors are key targets for treating obesity and metabolic disorders.
• Rimonabant and taranabant are known CB1 receptor modulators.
• Extensive research into CB1 receptor properties is ongoing.

Purpose of the Study:

• To design and synthesize novel substituted pyrimidines as potential CB1 receptor modulators.
• To evaluate the binding affinity and selectivity of synthesized compounds for CB1 receptors.
• To explore new therapeutic avenues for metabolic disorders.

Main Methods:

• Structure-based design inspired by taranabant.
• Efficient chemical synthesis of substituted pyrimidine derivatives.
• In vitro assays to determine binding affinity (IC50) and selectivity (CB2/CB1 ratio) for CB1 receptors.

Main Results:

• A series of substituted pyrimidines were successfully synthesized.
• Compound 13b, N4-((2S,3S)-3-(3-bromophenyl)-4-(4-chlorophenyl)butan-2-yl)-N6-butylpyrimidine-4,6-diamine, exhibited significant CB1 receptor binding.
• Compound 13b demonstrated good binding affinity (IC50=16.3nM) and selectivity (CB2/CB1=181.6) for the CB1 receptor.

Conclusions:

• Novel pyrimidine derivatives can be effectively designed and synthesized.
• Compound 13b represents a promising lead compound for CB1 receptor-targeted therapies.
• Further investigation into compound 13b's pharmacological profile is warranted for metabolic disorder treatment.